I was curious and saw this..
View attachment 112773
From 100 to 5.. sheesh
did you short it?
It was just a one day trade, not an investment. Bought around 8, sold at 13 the same day on news of a favorable phase 1 update. Only 100 shares because of the high risk. When I bought it, it was already up pretty big, but sometimes momentum can carry a stock to the next fib level, which would have been 13 or even 18. The stock did hit 17 that day, but I hesitated and sold at 13.
Biotechs are long shots plain and simple. Most of them usually have no products for sale and therefore rely on continual dilution of shareholders to fund ongoing drug trails.
Senti has an interesting approach to drug development (from their website):
Senti Bio is a clinical-stage company founded to create a new generation of smarter medicines for patients living with incurable diseases. To achieve this, we use synthetic biology to design and optimize proprietary Gene Circuits. Senti Bio’s Gene Circuits are created from novel combinations of DNA sequences to reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments.
While there is no guarantee this approach will be successful in whatever they are trying to treat, their initial phase 1 recently yield positive results. This is not uncommon however in early stages. There are different stages of drug development, but in a nutshell:
Preclincal / Patent stage - unlimited years. Preclinical results show promise, raise cash and devise studies with funds available.
Studies stage:
Phase 1, 1a, 1b, etc, results released. If good,
raise more money if you need it and proceed. Roughly 1-2 years or more
Phase 2, 2a, etc, results released. If good,
raise more money if you need it and proceed. Roughly 1-2 years or more
Phase 3, 3a, etc, results released. Roughly 1-2 years or more. If good, apply for New Drug Application with FDA and get ready for review.
If the drug fails any stage along the way, its game over. This sometimes means bankruptcy.
Once the NDA is filed after a successful phase 3 testing, an FDA panel reviews all data and votes on approval or rejection. The FDA panel's recommendation is sometimes followed and sometimes ignored by the FDA. A panel vote has a very big impact on the stock, second only to FDA full approval.
FDA approves or rejects drug. If rejected, stock goes to zero or near zero based on cash on hand.
Final stage / Product stage:
If approved Phase 4,
raise more money if you need it, find a manufacturer (if you need one) and prepare the drug for sale.
Now, after billions raised and massive dilution to original shareholders, you FINALLY have a product that will HOPEFULLY generate enough revenue to cover costs for more trials for other uses of your drug.
In Phase 4, the FDA, doctors and patients monitor for additional safety risks not initially revealed and the drug could be pulled if something comes up that harms people. If a drug is pulled, that could mean billions in damages to patients.
Most people avoid "science stocks" becuase of all the risks.
Senti is Phase 1. They have two other concepts that are not even that far. The market knows they are still early in development and will need to raise billions along the way, so the stock trades at a low market capitalization.
Best just to trade these.
